These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 38191557)
1. Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC. Panja S; Truica MI; Yu CY; Saggurthi V; Craige MW; Whitehead K; Tuiche MV; Al-Saadi A; Vyas R; Ganesan S; Gohel S; Coffman F; Parrott JS; Quan S; Jha S; Kim I; Schaeffer E; Kothari V; Abdulkadir SA; Mitrofanova A Nat Commun; 2024 Jan; 15(1):352. PubMed ID: 38191557 [TBL] [Abstract][Full Text] [Related]
2. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer. Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193 [TBL] [Abstract][Full Text] [Related]
3. Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment. Xu P; Yang JC; Chen B; Nip C; Van Dyke JE; Zhang X; Chen HW; Evans CP; Murphy WJ; Liu C J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37147019 [TBL] [Abstract][Full Text] [Related]
4. Luk IS; Shrestha R; Xue H; Wang Y; Zhang F; Lin D; Haegert A; Wu R; Dong X; Collins CC; Zoubeidi A; Gleave ME; Gout PW; Wang Y Clin Cancer Res; 2017 Mar; 23(6):1542-1551. PubMed ID: 27663589 [No Abstract] [Full Text] [Related]
5. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. Schalken J; Fitzpatrick JM BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596 [TBL] [Abstract][Full Text] [Related]
6. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC). Pal SK; Patel J; He M; Foulk B; Kraft K; Smirnov DA; Twardowski P; Kortylewski M; Bhargava V; Jones JO Cancer; 2018 Mar; 124(6):1216-1224. PubMed ID: 29266182 [TBL] [Abstract][Full Text] [Related]
7. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer. Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197 [TBL] [Abstract][Full Text] [Related]
8. Drug Resistance of Enzalutamide in CRPC. Chen X; Lu J; Xia L; Li G Curr Drug Targets; 2018; 19(6):613-620. PubMed ID: 28413979 [TBL] [Abstract][Full Text] [Related]
9. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Alumkal JJ; Sun D; Lu E; Beer TM; Thomas GV; Latour E; Aggarwal R; Cetnar J; Ryan CJ; Tabatabaei S; Bailey S; Turina CB; Quigley DA; Guan X; Foye A; Youngren JF; Urrutia J; Huang J; Weinstein AS; Friedl V; Rettig M; Reiter RE; Spratt DE; Gleave M; Evans CP; Stuart JM; Chen Y; Feng FY; Small EJ; Witte ON; Xia Z Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12315-12323. PubMed ID: 32424106 [TBL] [Abstract][Full Text] [Related]
10. Targeting CPT1B as a potential therapeutic strategy in castration-resistant and enzalutamide-resistant prostate cancer. Abudurexiti M; Zhu W; Wang Y; Wang J; Xu W; Huang Y; Zhu Y; Shi G; Zhang H; Zhu Y; Shen Y; Dai B; Wan F; Lin G; Ye D Prostate; 2020 Sep; 80(12):950-961. PubMed ID: 32648618 [TBL] [Abstract][Full Text] [Related]
11. Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients. Khan A; Mao Y; Tahreem S; Wei DQ; Wang Y Int J Biol Macromol; 2022 Oct; 218():856-865. PubMed ID: 35905763 [TBL] [Abstract][Full Text] [Related]
12. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. Graham L; Schweizer MT Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852 [TBL] [Abstract][Full Text] [Related]
13. Modeling Acquired Resistance to the Second-Generation Androgen Receptor Antagonist Enzalutamide in the TRAMP Model of Prostate Cancer. Cerasuolo M; Maccarinelli F; Coltrini D; Mahmoud AM; Marolda V; Ghedini GC; Rezzola S; Giacomini A; Triggiani L; Kostrzewa M; Verde R; Paris D; Melck D; Presta M; Ligresti A; Ronca R Cancer Res; 2020 Apr; 80(7):1564-1577. PubMed ID: 32029552 [TBL] [Abstract][Full Text] [Related]
14. Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer. Zhao J; Zhao Y; Wang L; Zhang J; Karnes RJ; Kohli M; Wang G; Huang H Oncotarget; 2016 Jun; 7(25):38551-38565. PubMed ID: 27221037 [TBL] [Abstract][Full Text] [Related]
15. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Wang Y; Chen J; Wu Z; Ding W; Gao S; Gao Y; Xu C Br J Pharmacol; 2021 Jan; 178(2):239-261. PubMed ID: 33150960 [TBL] [Abstract][Full Text] [Related]
16. Knocking down SOX2 overcomes the resistance of prostate cancer to castration via notch signaling. Du Z; Chen X; Zhu P; Lv Q; Yong J; Gu J Mol Biol Rep; 2023 Nov; 50(11):9007-9017. PubMed ID: 37716921 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of cholesterol biosynthesis overcomes enzalutamide resistance in castration-resistant prostate cancer (CRPC). Kong Y; Cheng L; Mao F; Zhang Z; Zhang Y; Farah E; Bosler J; Bai Y; Ahmad N; Kuang S; Li L; Liu X J Biol Chem; 2018 Sep; 293(37):14328-14341. PubMed ID: 30089652 [TBL] [Abstract][Full Text] [Related]
18. IAP Antagonists Enhance Apoptotic Response to Enzalutamide in Castration-Resistant Prostate Cancer Cells via Autocrine TNF-α Signaling. Pilling AB; Hwang O; Boudreault A; Laurent A; Hwang C Prostate; 2017 Jun; 77(8):866-877. PubMed ID: 28240376 [TBL] [Abstract][Full Text] [Related]
19. Lycopene enhances the sensitivity of castration-resistant prostate cancer to enzalutamide through the AKT/EZH2/ androgen receptor signaling pathway. Chen X; Yang G; Liu M; Quan Z; Wang L; Luo C; Wu X; Zheng Y Biochem Biophys Res Commun; 2022 Jul; 613():53-60. PubMed ID: 35533600 [TBL] [Abstract][Full Text] [Related]
20. Targeting prosurvival BCL2 signaling through Akt blockade sensitizes castration-resistant prostate cancer cells to enzalutamide. Pilling AB; Hwang C Prostate; 2019 Aug; 79(11):1347-1359. PubMed ID: 31228231 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]